+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Phosphodiesterase"

Enzyme Inhibitor Market Report 2025 - Product Thumbnail Image

Enzyme Inhibitor Market Report 2025

  • Report
  • January 2025
  • 200 Pages
  • Global
From
Phosphodiesterase (PDE) Inhibitors Market 2024-2028 - Product Thumbnail Image

Phosphodiesterase (PDE) Inhibitors Market 2024-2028

  • Report
  • December 2023
  • 165 Pages
  • Global
From
From
From
From
Nitric Oxide - Therapeutics, Markets and Companies - Product Thumbnail Image

Nitric Oxide - Therapeutics, Markets and Companies

  • Report
  • November 2021
  • 284 Pages
  • Global
From
Practical Enzymology. Edition No. 3 - Product Thumbnail Image

Practical Enzymology. Edition No. 3

  • Book
  • August 2019
  • 416 Pages
  • 16 Results (Page 1 of 1)
Loading Indicator

Phosphodiesterase (PDE) is a class of enzymes that catalyze the hydrolysis of phosphodiester bonds. They are involved in a variety of physiological processes, including signal transduction, metabolism, and cell division. In the pharmaceutical industry, PDE inhibitors are used to treat a variety of conditions, including erectile dysfunction, pulmonary hypertension, and asthma. PDE inhibitors work by blocking the action of the enzyme, allowing for increased levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This can lead to increased blood flow, relaxation of smooth muscle, and improved airway function. Some companies in the PDE market include Pfizer, GlaxoSmithKline, Merck, and Novartis. Show Less Read more